Clinical Trial

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Name: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer — clinical trial record (NCT07419880)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RECLAIM

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer

Trial Details

NCT Number	NCT07419880
Lead Sponsor	Fudan University
Conditions	Triple -Negative Breast Cancer
Enrollment	46 participants
Start Date	2026-01-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-19